Long non-coding RNA H19 correlates with unfavorable prognosis and promotes cell migration and invasion in ovarian cancer by Ma, Hainong et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
ISSN: 0017-0011
e-ISSN: 2543-6767
Long non-coding RNA H19 correlates with unfavorable
prognosis and promotes cell migration and invasion in ovarian
cancer
Authors:  Hainong Ma, Li Gao, Huimin Yu, Xu Song
DOI: 10.5603/GP.a2021.0079




This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
Articles in "Ginekologia Polska" are listed in PubMed. 
Powered by TCPDF (www.tcpdf.org)
ORIGINAL PAPER / GYNECOLOGY
Long non-coding RNA H19 correlates  with unfavorable  prognosis  and promotes  cell
migration and invasion in ovarian cancer
Hainong Ma, Li Gao, Huimin Yu, Xu Song
Hwamei Hospital, University of Chinese Academy of Sciences, Ning Bo, China
Corresponding author: 
Xu  Song  
Hwamei Hospital,  University Of Chinese Academy Of Sciences,  41 Xibei  Street,  315000
Ning  Bo,  China  
e-mail: xu.song@yandex.com
ABSTRACT 
The purpose of this study is to investigate the expression pattern of lncRNA H19 in OC 
tissues and to detect the ability of H19 to influence OC cell migration and invasion in vitro. 
We quantified the levels of H19 within the obtained cancerous and adjacent noncancerous 
tissues from 258 OC patients. H19 association with patient progression-free survival (PFS) 
was analyzed by a Kaplan-Meier plot. Expression levels of H19 were reduced by small 
interfering RNA transfection against H19 or restored by a H19 overexpression plasmid 
transfection in OC cells. H19 effects on OC cell migration and invasion in vitro were 
evaluated using wound-healing assay and transwell invasion assay. Wound healing assay and 
transwell invasion assay were used to evaluate the effects of H19 on OC cell migration and 
invasion in vitro. H19 is upregulated remarkably in primary OC tissues and human OC cell 
lines (OVCAR3, SKOV3, A2780, and Caov-3). We found that the median PFS was longer in 
patients with lower levels of H19 than in those with high levels, suggesting that 
overexpression of H19 was linked to poor prognosis in OC patients. Intriguingly, the depletion
of H19 expression induced by small interfering RNA inhibited the capability of migration and
invasion of OC cell lines. Restoration of H19 in OC cell lines significantly increased cell 
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migration and invasion. The key finding of the present study suggests that overexpression of 
H19 may be associated with an unfavorable prognosis for OC and is likely to be a possible 
contributory force involved in OC cell migration and invasion. H19 may provide a new and 
attractive target for future prognostic and therapeutic intervention of OC patients.
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INTRODUCTION
The continuing increase in the incidence and prevalence of ovarian cancer (OC) is a
cause for concern [1]. Up until now, OC represents the second most common gynecological
malignancies,  accounting  for  5%  of  all  cancers in  females [2].  On  an  annual  basis,  an
estimated 220,000 newly diagnosed OC cases worldwide [3]. Due to its late presentation and
often being  diagnosed at an advanced stage, most patients  succumb to recurrence and wide
metastasis,  explaining  the  high  mortality  rate [4]. OC  is  heterogeneous  in  nature  and
encompasses a collection of distinct histologic types, all with characteristic differences, which
is one of the major obstacles to improvement in this disease [5]. Early stage OC symptoms of
peritoneal  metastasis  are  generally  nonspecific,  which  subsequently  allows  for  frequent
misdiagnoses  as  well  as  underdiagnoses. Expression  patterns  of  a  recently  identified
biomarker family, long non-coding RNA (lncRNA), seem to be characteristic of tumor type
and developmental origin, including OC [6, 7].
Understanding of expression pattern and imprinting of H19 has progressed considerably
in recent years. The function of H19 in cancers remains to be elucidated due to its dual roles
acting either as a tumor suppressor or an oncogene. In a recent study, H19 is shown to inhibit
cancer progression [8, 9].  However, increasing evidence showed that H19 expression was
increased in several cancers such as breast cancer, lung cancer, gastric cancer, and bladder
cancer [10-13], highlighting its oncogenic properties. Intriguingly, several gain- or loss-of-
function studies demonstrated that H19 knockdown suppressed cell migration and invasion in
clear cell renal carcinoma and glioma [14, 15]. Few data support the functional role of H19 in
OC, and only a study reported by Zhu et al. proposed the contributory effect of H19 in OC
[16]. However, measurement of H19 in 70 pairs of OC tissue samples and normal controls
may limit the validity of results.
To investigate the expression and functional role of H19 in human ovarian cancer, in this
study  we  quantified  the  levels  of  H19  within  the  obtained  cancerous  and  adjacent
noncancerous tissues from OC patients.  Progression-free survival (PFS) was calculated by
following up with the patients. In addition, functional assays were applied in OC cells. Our




We collected cancerous and adjacent noncancerous tissues from 258 patients with OC
who were admitted into our hospital between January 2010 and January 2014. These patients
had a mean age of 48.5 ± 6.3 (ranging from 29 to 68 years old). The inclusion criteria for
patient enrollment: (1) an ovary biopsy with pathological and imaging diagnosis of OC; (2) an
initial  treatment  in our hospital  for OC; (3) no standard therapies,  such as chemotherapy,
surgery, or radiation therapy; (4) no previous history of the malignant tumors; (5) no distant
metastases or second primary tumor. The study protocol was approved by the Institutional
Ethics Committees at our hospital, and signed written informed consent was received from all
patients prior to enrollment.
Follow-up
The follow-up was scheduled at discharge, ranging from 3 to 36 months and consisting
of a telephone interview, a medical record review, or a hospital visit. The follow-up period
ended on December 2016. Among 258 cases, 6 cases were censored.  A follow-up rate of
93.0% was achieved. The primary endpoint was progression-free survival (PFS) was defined
as the time from diagnosis to either disease progression or relapse, or to death as a result of
any cause.
Cell preparation
Human  normal  ovarian  surface  epithelial  cell  lines  were  purchased  from  Shanghai
Huiying  Bio-technology  Co.,  Ltd.,  China  and  human  OC cell  lines,  OVCAR3,  SKOV3,
A2780,  and Caov-3,  from  Cell  Bank of  Chinese Academy of  Sciences,  Shanghai,  China.
SKOV3 cells  were cultured with McCoy's  5A Medium Modified (Sigma,  St.  Louis,  MO,
USA),  in  addition,RPMI-1640  medium  (Gibco  Company,  Grand  Island,  NY,  USA)  for
OVCAR3 and  A2780  cells,  and  DMEM-H  (Dulbecco's  Modified  Eagle's  Medium,  High
Glucose; Hyclone Laboratories, Logan, Utah, USA) for Caov-3 cells. All of the media were
supplemented with 10% fetal bovine serum (FBS, Gibco Company, Grand Island, NY, USA),
and all cells were incubated with 5% CO2 at 37°C. In order to evaluate the regulatory effects
of H19 on OC cells, SKOV3 cells showing the highest expression level of H19 were treated
by  small  interfering  RNA  (siRNA)  against  H19  and  a  H19  overexpression  plasmid,
respectively.  An  ineffective  scramble  of  siRNA,  a  siRNA  against  H19,  and  a  H19
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overexpression  plasmid  was  purchased  from Shanghai  GenePharma  Co.,  Ltd.  (Shanghai,
China).  The  Lipofectamine  2000  (Invitrogen  Corp.,  Carlsbad,  CA,  USA)  was  used  to
transfection operations according to the manufacturer’s instructions.
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Total RNA from tissues was isolated by TRIzol kits (Invitrogen, Carlsbad, CA, USA).
High-molecular-weight RNA was identified on a denaturing formaldehyde gel, then l μg of
RNA was reversely transcripted into cDNA using AMV-reverse transcriptase. Primers were
obtained from Invitrogen Inc., Carlsbad, CA, USA (Tab. 1). GAPDH was used as a loading
control. The PCR cycling reaction conditions: pre-denaturation at 94°C for 5 min, followed by
40 cycles of denaturation at 94°C for 40 s, annealing at 60°C for 40 s and extension at 72°C
for 1 min, followed by a final extension at 72°C for 10 min. PCR products were then subject
to agarose gel electrophoresis and analyzed by Opticon Monitor™ version 3.0 software (Bio-
Rad, Inc., Hercules, CA, USA). The Opticon monitor software (MJ Research, San Francisco,
CA, USA) was used to set the cycle threshold or Ct line manually. Data were analyzed by 2-
ΔΔCt method. Ct = Ct (target gene)-Ct (△ loading control), Ct = Ct (experimental group)-△△ △
Ct  (control  group).  The  experiment  was  repeated  three  times  independently,  with  the△
average obtained.
Transwell assay
Forty  eight  hours  after  transfection,  1  ×  105 cells  were  counted  and  inoculated  in
Matrigel-coated (80 μl of at a ratio of 1:8) transwell chambers containing 100 μl serum-free
DMEM medium. The Matrigel and cells  that remained on the upper side were wiped off
following 24 hours incubation. Then, the passed cells were fixed in 4% paraformaldehyde for
15 min and subsequently stained with 0.2% crystal violet for 10 min. Lastly, an inverted light
microscope (Olympus IX70, Tokyo, Japan, at × 200 magnification) was applied to count the
number  of  invading  cells  in  five  predetermined  fields  to  evaluate  cell  invasion.  All
experiments were independently performed at least three times.
Scratch test
On the back of the 6-well plate, use a marker pen to scratch an even with an interval
width of 0.8 cm. Each well was required to be crossed by more than five lines and added with
5 × 105 wells. When the cells grew to 100%, a uniform scratch was made in the center of the
well using a sterile micropipette tip, followed by washing with phosphate-buffered saline.
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After 58 hours incubation with 5% CO2 at 37°C, the wound healing was photographed for the
record. The rate of cell migration was assessed by the wound closure assay. All experiment
was also independently performed at least three times.
Statistical analysis
Statistical analysis was done using SPSS software (IBM SPSS Statistics, version 21.0,
Armonk,  NY, USA). Measurement  data  were expressed as the mean ± standard deviation
(SD); Fisher’s least  significant difference (LSD) was conducted for pairwise comparisons,
one-way analysis of variance (ANOVA) test for comparisons among multiple groups, and t-
test  for  comparisons  between  two  groups  when  demonstrating  normal  distribution.  The
association  with  survival  was  analyzed  initially  by  Kaplan-Meier  plot  and  log-rank  test.
Differences were accepted as significant if p-values less than 0.05.
RESULTS
Increased expression levels of H19 in OC primary tissues
Firstly,  in  order  to  evaluate  the  expression  pattern  of  H19 in OC, we quantified  the
expression levels of H19 within the obtained cancerous and adjacent noncancerous tissues
from 258 OC patients using RT-qPCR. We found that the expression levels of H19 in cancer
tissues (5.82 ± 0.67) were higher than those in adjacent noncancerous tissues (2.46 ± 0.29, P <
0.01).
Increased expression levels of H19 associated with poor survival of OC patients
Next,  we  classified  258  OC  patients  into  low-  and  high-level  groups  in  terms  of
expression levels of H19 in OC primary tissues to evaluate the association between the H19
expression levels and patient survival. We regarded patient PFS as the end point event. The
Kaplan Meier survival analysis (Fig. 1) showed the median PFS was longer in OC tissues
with low expression levels of H19 than in those with high expression levels (30.00 months vs.
24 months, P < 0.01). The data reveal that increased expression levels of H19 associated with
poor survival of OC patients.
Increased expression levels of H19 in OC cell lines
In  this  study,  we  chose  OC cell  lines  that  have  been  widely  used  in  OC research,
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especially in  functional  studies.  We examined the expression levels  of H19 in OVCAR3,
SKOV3,  A2780,  and  Caov-3  cell  lines  by  RT-qPCR.  The  result  showed  that  H19  was
increased in these four OC cell lines (P < 0.05, Figure 2) in which SKOV3 cell lines were
highest.
Silencing or restoring H19 in OC cells
Furthermore, we treated SKOV3 cells with an ineffective scramble of siRNA, siRNA
against H19, and a  H19 overexpression plasmid, respectively. We quantified the expression
levels of H19 in SKOV3 cells after different treatments by RT-qPCR. Indeed, H19 expression
was  restored  by H19  overexpression  plasmids,  while  H19  expression  was  suppressed  by
siRNA against H19 (P < 0.05). There was no significant difference in H19 expression levels
when  untreated  SKOV3  cells  were  compared  to  SKOV3  cells  treated  with  ineffective
scramble of siRNA. The data are shown in Figure 3.
The contributory effects of H19 on OC cell invasion and migration in vitro
To know the function of H19 in OC, we tested the effects of H19 on cell invasion and
migration  in  vitro by transwell  invasion  assay and wound-healingassay.  To determine  the
effect of H19 on the invasion potential of SKOV3 cells, we first carried out Matrigel invasion
assays(Figure  4A).  After  harvesting  for  48  h,  we found fewer  SKOV3 cells treated  with
siRNA against  H19 passed  through  Matrigel,  but  more  SKOV3  cells treated  with H19
overexpression  plasmids  passed  through Matrigel  (P <  0.05).  An  ineffective  scramble  of
siRNA did not significantly affect the invasion of SKOV3 cells (P > 0.05). Next, wound-
healing assay was used to determine the effect of H19 on the migration potential of SKOV3
cells  (Figure  4B).  After  harvesting for  48 h,  we found SKOV3 cells treated with  siRNA
against  H19  were  distinctively  less  migrated,  but  SKOV3  cells treated  with H19
overexpression plasmids healed the wound area faster (P < 0.05). An ineffective scramble of
siRNA did not significantly affect the migration of SKOV3 cells (P > 0.05). These findings
indicated that H19 could promote OC cell invasion and migration in vitro.
DISCUSSION
LncRNAs are becoming new candidates for diagnosing cancer disease, explaining the
mechanism of the pathogenesis and development of malignant tumors, predicting prognosis
and treating disease as targets in recent years [17]. In the present study, we demonstrate the
role of H19 as an oncogene in OC. Significantly, H19 was found to be increased in primary
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OC tissues and cell lines compared with adjacent normal tissues and normal cell lines, and
overexpression of H19 was linked to poor prognosis in OC patients. In addition, in order to
detect the ability of H19 to influence OC cell migration and invasion in vitro, the expression
levels of H19 were reduced by small interfering RNA transfection against H19, or restored by
a  H19  overexpression  plasmid  transfection  in  OC cells.  The  contributory  effects  of  this
lncRNA on cell migration and invasion indicate that H19 promotes tumorigenesis in OC.
Recently, H19 is highlighted for its association and involvement with many cancers, as it
plays an important role in regulating the expression of many genes that are essentials for
numerous  cellular  processes  [18].  Yang  et  al. reported  that  ectopic  expression  of  H19
increased cell proliferation, and cell apoptosis was induced in gastric cancer cell lines while
siRNA-mediated down-regulation of H19 [12]. They also found H19 affected the activity of
p53, and that this effect was leading to partial p53 inactivation. Suppression of H19 induces
invasion of serous borderline ovarian tumor cells via reducing PI3K/Akt-mediated inhibition
E-cadherin [19]. He et al. reported the mechanism that overexpression of H19 was sufficient
to increase the expression of E2F1 by which H19 promotes OC migration and invasion [14].
E2F1 exerts an anti-proliferative effect in OC cells, becoming a target for preventing OC [20].
Luo  and  his  team  found  that  upregulated  H19  promotes  bladder  cancer  cell  migration
associating with enhancer of zeste homolog 2 (EZH2), and that this association was leading to
Wnt/β-catenin activation and subsequent inhibition of E-cadherin [13]. EZH2 is found to be
upregulated  in  malignant  tumors  and  is  involved  in  metastasis,  including  OC,  and
overexpression of EZH2 facilitates OC cell invasion and migration [21]. An unexpected mode
of  action  of  H19  can  antagonize  the  let-7  family  of  microRNAs  [22].  An  increase  of
microRNA let-7i expression induces OC cell apoptosis, which is the mechanism of propofol,
can effectively inhibit proliferation and induce apoptosis  in OC cells [23]. Inhibited let-7i
expression remarkably reduced the  resistance  of  OC cells  to  the chemotherapy drug,  and
decreased let-7i expression was associated with the shorter PFS of OC patients, which may
explain the fact that overexpression of H19 was linked to poor prognosis in OC patients [24].
A high  H19  expression  contributes  to  poor  overall  survival  and  can  be  served  as  an
independent  predictor  of  the  overall  survival  of  gastric  cancer  patients  [25],  which  may
provide evidence for the prognostic role of H19 in OC, as reflected in our study.
Based on the key findings obtained from our study, we believe that H19 could potentially
act  as  atherapeutic  target.  The  reasons  were  as  follows:  (1)  H19  expression  levels  are
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significantly increased in tissues and cell lines of OC; (2) H19 in relation to OC prognosis; (3)
inhibiting H19 suppresses OC cell migration and invasion.
Taken together, our findings indicate that H19 plays a vital role in the development and
progression of OC. The development of downregulation of this oncogenic lncRNAs based on
H19-based therapeutic strategies may provide new and promising alternative therapeutics for
future OC treatment. However, a larger sample size and longer follow-up period are required
to confirm the correlation between H19 expression level and overall 5-year survival rate of
OC patients. Meanwhile, more attention should be paid to exploring the mechanism of H19
and its interaction with oncogenes, and a new target should be discovered to cope with the
highly migratory and invasive OC.
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Figure  1. The  Kaplan-Meier  plot  showed  that  increased  expression  levels  of  H19  are
associated with poor survival of OC patients
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Figure 2.  Increased expression  levels  of  H19 in OC cell  lines,  determined by RT-qPCR.
Compared with IOSE80 cells, OVCAR3, SKOV3, A2780, and Caov-3 cells showed higher
expression levels of H19 (* — P < 0.05). Among these four OC cell lines, SKOV3 cell lines
exhibited the highest expression levels of H19
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Figure 3. H19 expression was suppressed or restored in SKOV3 cells, verified by RT-qPCR;
* — P < 0.05 compared with untreated SKOV3 cells
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Figure 4. H19 could promote OC cell invasion and migration; A. wound-healing assay was
used to determine the effect of H19 on the invasion potential of SKOV3 cells (× 200); B.
transwell invasion assay was used to determine the impact of H19 on migration potential of
SKOV3 cells (×200); * — P < 0.05 compared with untreated SKOV3 cells
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